Therapeutic agents intended to reduce dental plaque and prevent tooth decay are often removed by saliva and the act of swallowing before they can take effect. But a team of researchers has developed a way to keep the drugs from being washed away.
Damage to neural tissue is typically permanent and causes lasting disability in patients, but a new approach has recently been discovered that holds incredible potential to reconstruct neural tissue at high resolution in three dimensions.
By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists at the Laboratoire Matière et Systèmes Complexes (CNRS/Université Paris Diderot) and the Laboratoire Physicochimie des Electrolytes et Nanosystèmes Interfaciaux (CNRS/UPMC), obtained total tumor regression in mice.
Chemists, biologists and pharmacologists deal with the question of how complex active substances can be introduced into cells such that they are rapidly and easily available. Building on earlier research, interdisciplinary teams of scientists, with biology Professor M. Cristina Cardoso (TU Darmstadt), physics Professors Henry D. Herce (RPI, NY, USA and TU Darmstadt) and Angel E. Garcia (RPI, NY, USA), and chemistry Professor Christian P. R. Hackenberger (FMP, Berlin), have made some important advancements.
Nanomedicine has published a special focus issue on the combined force of nanomedicine and regenerative medicine; two fields that continue to develop at a dramatic pace.
Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice.
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions, today announced that upon a scheduled interim review, the study's Steering Committee recommended to stop enrollment early in its first-in-human study of investigational drug MAT9001 due to the study having enrolled a sufficient number of subjects (42 to date) necessary to demonstrate primary and secondary endpoints.
Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice President, Vaccine Development, will present, "Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7th International Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. at the Washington Marriott Metro Center in Washington, D.C.
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Department of Neurosurgery at Kiel University Hospital (UKSH), headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.